Diarylureas as Antitumor Agents
Source abstract
Abstract
The diarylurea is a scaffold of great importance in medicinal chemistry as it is present in numerous heterocyclic compounds with antithrombotic, antimalarial, antibacterial, and anti-inflammatory properties. Some diarylureas, serine-threonine kinase or tyrosine kinase inhibitors, were recently reported in literature. The first to come into the market as an anticancer agent was sorafenib, followed by some others. In this review, we survey progress over the past 10 years in the development of new diarylureas as anticancer agents.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Synthesis and biological activity · Synthesis and Biological Activity · Synthesis and Catalytic Reactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, 70126 Bari, Italy
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy
References (100+)
Show source-provided references
1. Urea derivatives in modern drug discovery and medicinal chemistry10.1021/acs.jmedchem.9b01541 ↗
2. The history of barbiturates a century after their clinical introduction
3. Ureas: Applications in Drug Design10.2174/0929867323666161129124915 ↗
4. Short Notes on Diaryl Ureas Derivatives
5. Diaryl urea: A privileged structure in anticancer agents10.2174/0929867323666160411142532 ↗
6. Ceramella, J., Mariconda, A., Rosano, C., Iacopetta, D., Caruso, A., Longo, P., Sinicropi, M.S., and Saturnino, C. (2020). α–ω Alkenyl-bis-S-guanidine thiourea dihydrobromide affects HeLa cell growth hampering tubulin polymerization. ChemMedChem.10.1002/cmdc.202000544 ↗
7. Research Progress of Diphenyl Urea Derivatives as Anticancer Agents and Synthetic Methodologies10.2174/1570193X15666181029130418 ↗
8. 3-(Dipropylamino)-5-hydroxybenzofuro [2, 3-f] quinazolin-1 (2H)-one (DPA-HBFQ-1) plays an inhibitory role on breast cancer cell growth and progression10.1016/j.ejmech.2015.11.004 ↗
9. N-heterocyclic carbene complexes of silver and gold as novel tools against breast cancer progression10.4155/fmc-2016-0160 ↗
10. New insights for the use of quercetin analogs in cancer treatment10.4155/fmc-2017-0118 ↗
11. Design, synthesis, and biological evaluation of novel water-soluble N-mustards as potential anticancer agents10.1016/j.bmc.2010.11.005 ↗
12. Recent progress in the identification of BRAF inhibitors as anticancer agents10.1016/j.ejmech.2013.11.018 ↗
13. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors10.1016/j.ejmech.2014.04.007 ↗
14. Biphenyl derivatives incorporating urea unit as novel VEGFR-2 inhibitors: Design, synthesis and biological evaluation10.1016/j.bmc.2013.11.027 ↗
15. A novel anticancer diarylurea derivative HL-40 as a multi-kinases inhibitor with good pharmacokinetics in Wistar rats10.1016/j.biopha.2014.11.003 ↗
16. Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families10.1016/j.bmcl.2012.03.035 ↗
17. Carbazole derivatives as kinase-targeting inhibitors for cancer treatment10.2174/1389557520666200117144701 ↗
18. Tella, S.H., Kommalapati, A., and Mahipal, A. (2020). Systemic therapy for advanced hepatocellular carcinoma: Targeted therapies. Chin. Clin. Oncol.10.21037/cco-20-117 ↗
19. Sorafenib: Key lessons from over 10 years of experience10.1080/14737140.2019.1559058 ↗
20. Mazzocca, A., Napolitano, A., Silletta, M., Spalato Ceruso, M., Santini, D., Tonini, G., and Vincenzi, B. (2019). New frontiers in the medical management of gastrointestinal stromal tumours. Ther. Adv. Med. Oncol., 11.10.1177/1758835919841946 ↗
21. Regorafenib (BAY 73-4506) in advanced colorectal cancer: A phase I study10.1038/bjc.2012.153 ↗
22. Sorafenib in advanced hepatocellular carcinoma10.1056/NEJMoa0708857 ↗
23. Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus
24. Regorafenib in gastrointestinal stromal tumors10.2217/fon.14.101 ↗
25. Molecularly imprinted hydrogels for sustained release of sunitinib in breast cancer therapy10.1002/pat.4512 ↗
26. Mossenta, M., Busato, D., Baboci, L., Di Cintio, F., Toffoli, G., and Dal Bo, M. (2019). New insight into therapies targeting angiogenesis in hepatocellular carcinoma. Cancers, 11.10.3390/cancers11081086 ↗
27. Linifanib exerts dual anti-obesity effect by regulating adipocyte browning and formation10.1016/j.lfs.2019.01.047 ↗
28. Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma10.2217/fon-2020-0443 ↗
29. Bournez, C., Carles, F., Peyrat, G., Aci-Sèche, S., Bourg, S., Meyer, C., and Bonnet, P. (2020). Comparative assessment of protein kinase inhibitors in public databases and in PKIDB. Molecules, 25.10.3390/molecules25143226 ↗
30. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib10.2217/fon-2019-0633 ↗
31. Sorafenib: A clinical and pharmacologic review10.1517/14656566.2010.496453 ↗
32. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond10.1016/j.ctrv.2018.05.006 ↗
33. Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib10.2147/CMAR.S233448 ↗
34. Medical Management of Hepatocellular Carcinoma10.1200/JOP.2017.022996 ↗
35. Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation10.1016/j.biopha.2017.01.077 ↗
36. LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)10.1093/annonc/mdz446.002 ↗
37. Pinato, D.J., Kaneko, T., Saeed, A., Pressiani, T., Kaseb, A., Wang, Y., Szafron, D., Jun, T., Dharmapuri, S., and Naqash, A.R. (2020). Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: Adjunctive role of the ALBI grade. Cancers, 12.10.3390/cancers12071862 ↗
38. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer10.2147/IJN.S104119 ↗
39. Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix10.1080/10717544.2016.1245371 ↗
40. Investigation on graphdiyne nanosheet in adsorption of sorafenib and regorafenib drugs: A DFT approach10.1016/j.molliq.2019.01.003 ↗
41. COVID-19: Could Irisin Become the Handyman Myokine of the 21st Century?10.2174/2666796701999200617154655 ↗
42. Systemic treatment of patients with gastrointestinal cancers during the COVID-19 outbreak: COVID-19-adapted recommendations of the national cancer institute of Milan10.1016/j.clcc.2020.05.004 ↗
43. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib10.1177/1756283X15618129 ↗
44. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients10.1016/j.jhep.2019.08.015 ↗
45. Tyrosine kinase inhibitors and mesenchymal stromal cells: Effects on self-renewal, commitment and functions10.18632/oncotarget.12649 ↗
46. Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in Sorafenib-induced cytoskeletal rearrangement in hepatoma cells10.1002/jcp.22160 ↗
47. Zinc sensitizes prostate cancer cells to sorafenib and regulates the expression of Livin10.1093/abbs/gmt017 ↗
48. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K110.1007/s13402-018-0370-z ↗
49. Ettrich, T.J., and Seufferlein, T. (2018). Regorafenib. Small Molecules in Oncology, Springer.10.1007/978-3-319-91442-8_3 ↗
50. Molecular insight of regorafenib treatment for colorectal cancer10.1016/j.ctrv.2019.101912 ↗
51. Benefit-risk summary of regorafenib for the treatment of patients with advanced hepatocellular carcinoma that has progressed on sorafenib10.1634/theoncologist.2017-0422 ↗
52. Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study
53. Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC)10.1200/JCO.2017.35.4_suppl.721 ↗
54. Adenis, A., de la Fouchardiere, C., Paule, B., Burtin, P., Tougeron, D., Wallet, J., Dourthe, L.M., Etienne, P.L., Mineur, L., and Clisant, S. (2016). Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: Results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer, 16.10.1186/s12885-016-2559-8 ↗
55. Optimizing treatment outcomes with regorafenib: Personalized dosing and other strategies to support patient care10.1634/theoncologist.2013-0059 ↗
56. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) (2020, November 12). Colon Cancer. Version 4.2018 National Comprehensive Cancer Network. Available online: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
57. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): A randomised, multicentre, open-label, phase 2 study10.1016/S1470-2045(19)30272-4 ↗
58. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial10.1016/S0140-6736(16)32453-9 ↗
59. Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma10.1080/15548627.2019.1598752 ↗
60. Han, K.M., Kang, R.J., Jeon, H., Lee, H., Lee, J.S., Park, H.H., Jeon, S.G., Suk, K., Seo, J., and Hoe, H.S. (2020). Regorafenib regulates AD pathology, neuroinflammation, and dendritic spinogenesis in cells and a mouse model of AD. Cells, 9.10.3390/cells9071655 ↗
61. Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol [3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase10.1016/j.bmc.2018.08.013 ↗
62. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: From bench to bedside10.1186/1756-8722-2-33 ↗
63. Inhibition of phosphorylation of the colonystimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors10.1158/1535-7163.MCT-05-0359 ↗
64. Linifanib: Current status and future potential in cancer therapy10.1586/14737140.2015.1042369 ↗
65. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)10.1016/j.bmc.2013.03.083 ↗
66. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma10.1002/cncr.27758 ↗
67. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial10.1200/JCO.2013.54.3298 ↗
68. Linifanib (ABT-869) potentiates the efficacy of chemotherapeutic agents through the suppression of receptor tyrosine kinase-mediated akt/mtor signaling pathways in gastric cancer
69. Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer
70. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties10.1158/0008-5472.CAN-05-4290 ↗
71. Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells10.1038/srep44075 ↗
72. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a phase III trial10.1200/JCO.2012.47.4940 ↗
73. Salgia, N.J., Zengin, Z.B., and Pal, S.K. (2020). Tivozanib in renal cell carcinoma: A new approach to previously treated disease. Ther. Adv. Med. Oncol., 12.10.1177/1758835920923818 ↗
74. Final data analysis supports tivozanib as superior treatment for patients with RCC
75. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): A phase 3, multicentre, randomised, controlled, open-label study10.1016/S1470-2045(19)30735-1 ↗
76. Final overall survival results from a phase 3 study to compare tivozanib to sorafenib as third-or fourth-line therapy in subjects with metastatic renal cell carcinoma10.1016/j.eururo.2020.08.007 ↗
77. Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): A phase 3, multicentre, randomised, controlled, open-label study10.21037/atm.2020.03.217 ↗
78. Iyer, R.V., Li, D., Dayyani, F., Needle, M.N., and Abrams, T.A. (2020). A phase Ib/II, open-label study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma. J. Clin. Oncol., 38.10.1200/JCO.2020.38.15_suppl.e16599 ↗
79. Swetzig, W.M., Lurain, J.R., Berry, E., Pineda, M.J., Shahabi, S., Perry, L., Neubauer, N.L., Nieves-Neira, W., Schink, J.C., and Schiller, A. (2019). Efficacy and safety of tivozanib in recurrent, platinum resistant ovarian, fallopian tube or primary peritoneal cancer. J. Clin. Oncol., 37.10.1200/JCO.2019.37.15_suppl.5538 ↗
80. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells10.1038/srep45954 ↗
81. Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma10.1080/13543784.2019.1555236 ↗
82. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma10.1007/s11060-016-2332-5 ↗
83. Tivozanib: Status of development10.1007/s11912-015-0451-3 ↗
84. A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies10.1016/j.clcc.2014.12.001 ↗
85. BATON-CRC: A phase II randomized trial comparing tivozanib plus mFOLFOX6 with bevacizumab plus mFOLFOX6 in stage IV metastatic colorectal cancer10.1158/1078-0432.CCR-15-3117 ↗
86. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants10.1016/j.ccell.2019.04.006 ↗
87. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial10.1016/S1470-2045(20)30479-4 ↗
88. US Food and Drug Administration (2020, November 12). QINLOCK Prescribing Information, Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf.
89. Gastrointestinal stromal tumor—A review of clinical studies10.1177/1078155219846955 ↗
90. Jawhar, M., Gotlib, J., and Reiter, A. (2020). Tyrosine kinase inhibitors in systemic mastocytosis. Mastocytosis, Springer.10.1007/978-3-030-27820-5_15 ↗
91. Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology10.1080/14737140.2020.1708198 ↗
92. Design, synthesis and molecular modeling of phenyl dihydropyridazinone derivatives as B-Raf inhibitors with anticancer activity10.1016/j.bioorg.2020.104148 ↗
93. Direct binding of microRNA-21 pre-element with Regorafenib: An alternative mechanism for anti-colorectal cancer chemotherapy?10.1016/j.jmgm.2017.02.004 ↗
94. Andrographolide binds to ATP-binding pocket of VEGFR2 to impede VEGFA-mediated tumor-angiogenesis10.1038/s41598-019-40626-2 ↗
95. New sorafenib derivatives: Synthesis, antiproliferative activity against tumour cell lines and antimetabolic evaluation10.3390/molecules17011124 ↗
96. Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms10.18632/oncotarget.4514 ↗
97. BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models10.18632/oncotarget.9657 ↗
98. Pre-Clinical Evaluation of a Novel DNA Crosslinking Agent, BO-1055 in B-Cell Lymphoma10.1182/blood.V124.21.5483.5483 ↗
99. Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach10.1016/j.ejmech.2014.02.018 ↗
100. Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents10.1016/j.ejmech.2015.10.045 ↗